From April 1, pharmaceutical company Mundipharma will introduce its new non-crushable OxyContin tablets and withdraw the original version of the medicine from pharmacy shelves.
The Pharmacy Guild of Australia has warned its members to be on the look out for people with fraudulent scripts trying to obtain the last supplies of the old, crushable version of the drug in the next few weeks.
“It is expected in the transition period around the introduction of the reformulation, there will be an increase in the number of forged prescriptions for oxycodone prescriptions being presented to pharmacies. Pharmacists must ensure that all oxycodone prescriptions are safe and appropriate,” the newsletter said.
The savings to taxpayers could, however, be short-lived because the patent on OxyContin expires in the middle of this year and generic versions of the drug that are crushable will be allowed to be sold.
Last year the United States Food and Drug Administration intervened to prevent the sale of crushable forms of the drug there after 48 attorneys general signed a letter calling on it to help stamp out the diversion of the drug to the illegal market.
Mundipharma Managing Director Jane Orr said she wanted the Australian government to consider “new standards to recognise the utilisation of abuse-resistant technologies.”
Banning non crushable forms of OxyContin would give Mundipharma a significant market advantage and could delay any savings taxpayers might make from the introduction of cheaper generic versions of the drug.
This would need to be weighed against gains made in stamping out part of the illegal drug trade and reduction in health costs related to deaths and overdoses caused by the medicine.